Selskabets formål er udvikling, produktion og salg af et testsystem til diagnosticering af kontaktallergi, samt al virksomhed som efter bestyrelsens skøn er beslægtet hermed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 78.5 mio. | 16.9 mio. | 114.1 mio. | 47.4 mio. | 50 | |
CVR: 89669510
Secondary names: MEKOS ApS, MEKOS LABORATORIES ApS
Compared to 130 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
The financial health of SMARTPRACTICE DENMARK ApS appears robust, with consistent revenue growth over the past five years. Revenue increased from 59.4 million DKK in 2021 to 78.5 million DKK in 2025, while profit has also shown an upward trend, peaking at 19.7 million DKK in 2024 before slightly declining to 16.9 million DKK in 2025. The company's equity remains strong, totaling 47.4 million DKK in 2025, although it has seen a slight decrease from the previous year. With a solid profit margin and increasing revenues, the company is well-positioned within the pharmaceutical manufacturing industry, though attention should be paid to the slight fluctuations in profit and equity levels.
AI-generated summary
Companies in the same industry and area
companydata.dk